Can-Fite BioPharma (CANF) said Tuesday that the US Food and Drug Administration has approved the compassionate use treatment with anti-cancer drug Namodenoson for a pancreatic cancer patient in the US.
The clinical-stage company said it is currently evaluating Namodenoson in a late-stage clinical trial for advanced liver cancer, while it is also testing the drug in a phase 2a pancreatic cancer clinical trial in Israel.
The FDA has also granted orphan drug designation to Namodenoson, the company said.
Shares of the company rose 12% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.